Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company advancing targeted therapies for challenging cancers. This page provides investors and researchers with direct access to official announcements and verified updates about the company’s oncology programs.
Key resources include: Clinical trial progress for lead candidate DKN-01 (targeting DKK1), developments in FL-301 (Claudin18.2 program), partnership announcements, and financial disclosures. All content is sourced from authorized releases to ensure reliability.
Users benefit from: Timely updates on regulatory milestones, research collaborations, and pipeline advancements in gastrointestinal/gastroesophageal cancers. Content is organized chronologically for efficient tracking of material events.
Bookmark this page to monitor Leap Therapeutics’ progress in developing precision antibody therapies, with new updates added as official announcements become available.
Leap Therapeutics, Inc. (NASDAQ: LPTX) announced its presentation of long-term follow-up data from Part A of the DisTinGuish study at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023, in Chicago, IL. This Phase 2 clinical trial evaluates the efficacy of DKN-01, an anti-DICKKOPF-1 antibody, in combination with tislelizumab and chemotherapy for patients with advanced gastroesophageal adenocarcinoma (GEA). The presentation will occur on June 5, 2023, at 11:30 a.m. ET, featuring Samuel J. Klempner from Harvard Medical School. The study aims to assess the safety and effectiveness of DKN-01 in various patient groups, as Leap continues to develop targeted cancer therapies.
Leap Therapeutics, Inc. (Nasdaq: LPTX) has completed enrollment in Part A of the Phase 2 DeFianCe study, which evaluates DKN-01, its anti-Dickkopf-1 antibody, in combination with bevacizumab and chemotherapy for advanced colorectal cancer (CRC).
This milestone is considered critical for the DKN-01 program, reflecting strong interest from investigators and patients. The study enrolled 33 patients in Part A and is set to expand into Part B with a total of 130 patients. The primary goal is to assess progression-free survival, with secondary objectives including overall response rate and overall survival.
DKN-01 is designed to disrupt the immune suppressive tumor microenvironment associated with CRC, offering potential therapeutic benefits. Initial data from the study is expected in mid-2023.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
